Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-1826, Adelbeli monoclonal antibody injection, Bevacizumab monoclonal antibody injection obtained drug clinical trial approval letter.

Jiangsu Hengrui Pharmaceuticals (01276) announced recently that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceuticals Co., Ltd., have received approval from the National Medical Products Administration to conduct clinical trials on injection SHR-1826, Atezolizumab injection, and Bevacizumab injection. Injection SHR-1826 is an antibody-drug conjugate targeting c-MET, which kills tumor cells by specifically binding to target antigens on the surface of tumor cells and being internalized into the cells. Atezolizumab injection is a humanized anti-PD-L1 monoclonal antibody developed by the company, which blocks the PD-1/PD-L1 pathway that causes tumor immune tolerance by specifically binding to the PD-L1 molecule, thereby reactivating the immune system's anti-tumor activity to treat tumors. The company's Atezolizumab injection (brand name: Aiyeli) was approved for marketing in March 2023, with the indication for first-line treatment in combination with carboplatin and etoposide for extensive-stage small cell lung cancer patients. Bevacizumab is a humanized anti-VEGF monoclonal antibody developed through collaboration between Sino-foreign pharmaceutical companies and Roche's subsidiary Genentech. It was approved for marketing in the US in 2004 under the brand name Avastin and is currently marketed and sold in China and multiple countries worldwide. The company's Bevacizumab injection was approved for marketing in June 2021, with multiple Bevacizumab injections already approved for marketing in China.